Agenus provides update on ROBBIN Phase 3 execution and BOT+BAL immunotherapy program

Agenus provides update on ROBBIN Phase 3 execution and BOT+BAL immunotherapy program
Agenus shares trial, therapy update

Agenus has released updates on the execution of its ROBBIN Phase 3 clinical trial and developments in its BOT+BAL immunotherapy initiative targeting colorectal cancer.

The company also discussed the rationale for using immunotherapy before surgical intervention. These updates were shared during a recent stakeholder webcast, with a replay now available to interested parties.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.